Ipamorelin Dosage Guide: Complete Protocol for Safe Administration

Medically reviewed by the BHRC Clinical Team — Beverly Hills Rejuvenation Center · Written by Sam Brooks · Published / Reviewed July 24, 2026

Medical disclaimer: This article is educational and is not medical advice. The dosing figures below describe how licensed clinicians titrate ipamorelin in a supervised setting; they are not self-administration instructions. Ipamorelin is not an FDA-approved drug, and it has never been approved for anti-aging, growth-hormone stimulation, or body-composition use. Do not obtain, reconstitute, or inject any peptide without a qualified prescriber directing your care. Always consult a physician before beginning any peptide therapy.

Quick Ipamorelin Dosing Summary

In physician-supervised protocols, ipamorelin is most commonly dosed at 100–300 mcg per injection, given subcutaneously one to three times per day, with the single most important dose taken at bedtime on an empty stomach. A typical starting point is 100 mcg once nightly, titrated upward based on tolerance and IGF-1 labs. Because ipamorelin saturates its receptor at roughly 1 mcg per kilogram of body weight, doses far above ~300 mcg per shot rarely add growth-hormone release. All figures below are provider-directed education, not a prescription.

The rest of this guide expands every one of those numbers into a full clinical protocol: what ipamorelin is and how it works, how it is dosed by experience tier, the exact milligram-to-insulin-unit reconstitution math for 5 mg, 10 mg, and 2 mg vials, injection technique, timing, cycling, side effects, how it compares to CJC-1295 and sermorelin, monitoring, candidacy, and an honest, dated look at the regulatory status. Schedule a Peptide Therapy Consultation with a BHRC physician to find out whether any of it is appropriate for you.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that belongs to a class of compounds called growth hormone secretagogues (GHS). It works by telling the pituitary gland to release a pulse of the body’s own growth hormone (GH) rather than by introducing GH from outside. It is frequently described as a “ghrelin mimetic” because it acts on the same receptor as the hunger hormone ghrelin.

A Selective Ghrelin-Receptor Agonist

Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a) — the receptor ghrelin naturally activates — on the somatotroph cells of the anterior pituitary. Activating that receptor does two things at once: it directly stimulates a GH pulse, and it suppresses somatostatin, the hormone that acts as the body’s “brake” on GH release. The result is a clean, short-lived spike in circulating growth hormone that then triggers the liver to produce insulin-like growth factor 1 (IGF-1), the downstream mediator of most of GH’s anabolic and reparative effects.

How Ipamorelin Differs From GHRH Peptides

It is important not to confuse ipamorelin with growth-hormone-releasing hormone (GHRH) analogs such as CJC-1295, sermorelin, or tesamorelin. Those peptides act on a different receptor (the GHRH receptor) and essentially increase the size of the GH reservoir the pituitary can release. Ipamorelin, by contrast, acts through the ghrelin pathway to trigger the release itself. Because the two mechanisms are complementary — one fills the tank, the other opens the valve — ipamorelin and a GHRH analog are often combined, which is the entire rationale behind the popular CJC-1295/Ipamorelin stack covered in our CJC-1295 & Ipamorelin dosage guide.

Why “Selective” Matters

Ipamorelin was first described by Raun and colleagues in 1998 as “the first selective growth hormone secretagogue.” The word “selective” is the whole point. Older GH-releasing peptides in the same family — GHRP-6 and GHRP-2 — reliably raise GH but also spill over onto other pituitary outputs, notably cortisol, prolactin, and ACTH. Ipamorelin was engineered to trigger a GH pulse comparable in potency to GHRP-6 while leaving cortisol, prolactin, ACTH, and appetite-driving effects largely unchanged at therapeutic doses. That cleaner profile is the main reason clinicians favor it over the older secretagogues.

Studied Benefits (and Honest Evidence Limits)

Research and clinical experience associate GH and IGF-1 optimization with improved body composition, better sleep, faster recovery, and connective-tissue support. The honest caveat is essential: ipamorelin’s best-documented human data come from short pharmacokinetic studies and a postoperative-ileus (bowel-recovery) trial program — not from long-term anti-aging or body-composition trials. Much of the mechanistic and outcome evidence comes from animal models. Every benefit below is therefore framed as “research suggests” or “studied for,” never as a guaranteed outcome.

Ipamorelin Benefits: What the Research Supports

Before touching a dose, it is worth grounding why patients pursue ipamorelin — and being precise about how strong the evidence is behind each claim. The benefits below are the ones most consistently discussed in the literature and clinical practice, framed honestly as “studied for” rather than promised.

Body Composition and Fat Metabolism

Growth hormone drives lipolysis (the breakdown of stored fat) and supports lean tissue, and IGF-1 mediates many of its anabolic effects. In supervised GH-optimization protocols, patients most commonly pursue reduced visceral (abdominal) fat and preserved or modestly increased lean mass. The effect is real physiologically but gradual and diet-dependent — ipamorelin supports body-composition goals; it does not override caloric balance or training. It is not a weight-loss drug in the way a GLP-1 medication is, and it should never be marketed as one.

Sleep Quality

The body’s single largest natural GH pulse coincides with early slow-wave (deep) sleep. Because a bedtime ipamorelin dose amplifies that already-occurring pulse, deeper, more restorative sleep is one of the earliest and most frequently reported subjective benefits — often noticed within the first one to two weeks. Better sleep, in turn, feeds back into recovery, mood, and daytime energy.

Recovery, Connective Tissue, and Bone

IGF-1 supports collagen synthesis and tissue repair, and ipamorelin specifically has rodent data showing longitudinal bone growth and increased bone mineral content, including studies suggesting it can counteract glucocorticoid-induced bone loss. Patients commonly report faster recovery between training sessions and reduced soreness. The strongest of this evidence remains animal-model data, so human recovery and bone benefits are best described as biologically plausible and anecdotally supported rather than proven.

Skin Quality and Anti-Aging

Improvements in skin firmness and hydration are a popular reported effect and are biologically plausible through IGF-1’s role in collagen production and fibroblast activity. This is, however, the weakest-evidenced benefit and should be viewed as a possible secondary effect rather than a primary reason to start therapy.

Appetite and Gut Motility

Because ipamorelin activates the ghrelin receptor, it can mildly increase appetite — though far less than non-selective secretagogues like GHRP-6. That same ghrelin-receptor action accelerates gastric emptying and gut motility, which is why ipamorelin was actually studied in a formal human clinical program for postoperative ileus (the temporary bowel shutdown after abdominal surgery). That program remains the largest source of controlled human safety and tolerability data on the molecule, even though the indication is unrelated to how ipamorelin is used in wellness settings.

Ipamorelin Dosing Protocols Based on Clinical Research

Because there is no FDA-approved label for ipamorelin, “dosing” is derived from its pharmacokinetics, the doses used in human research, and physician compounding experience. The single most useful concept below is the tiered dosing chart — showing mcg per dose and daily frequency — because most competing resources bury the numbers in prose or give a single vague figure.

Standard Ranges (the dosing chart)

The following tiers describe how clinicians commonly titrate ipamorelin. Providers almost always begin at the beginner tier to assess individual tolerance and response before advancing.

Note that the total daily dose climbs mainly through frequency, not through ever-larger single injections. That is deliberate, and it follows directly from ipamorelin’s pharmacology, explained next.

Research-Based Protocols

The human pharmacokinetic work on ipamorelin (Gobburu et al., 1999) infused doses on a per-kilogram basis and found dose-proportional kinetics with a short terminal half-life of roughly two hours and a single, self-limiting GH pulse peaking under an hour after administration. The practical translation for subcutaneous dosing is threefold: (1) each dose produces one discrete pulse, so spacing doses across the day produces multiple pulses; (2) the short half-life is why ipamorelin is dosed daily rather than weekly; and (3) because GH returns to baseline quickly, timing each dose around low insulin (fasted / bedtime) matters a great deal. The fixed-mcg tiers above are what compounding pharmacies and clinics actually prescribe; the weight-based research framing simply explains why those numbers were chosen.

Clinical Trial Data

Two bodies of human evidence anchor ipamorelin dosing. First, the foundational pharmacology by Raun et al. (1998) established ipamorelin’s high GH-releasing potency (an ED₅₀ near 2.3 nmol/kg in swine, comparable to GHRP-6) alongside its defining selectivity — GH release without meaningful cortisol, prolactin, ACTH, FSH, LH, or TSH elevation. Second, the postoperative-ileus program (a randomized, placebo-controlled proof-of-concept study by Beck and colleagues, using intravenous ipamorelin around 0.03 mg/kg twice daily in bowel-resection patients) provides controlled human safety and tolerability data. Crucially, there is no published long-term human randomized controlled trial of ipamorelin for anti-aging, muscle gain, or fat loss — the single most important limitation to keep in mind when reading any dosing chart, including this one.

The Saturation-Dose Concept

A practical rule many clinicians follow is the “saturation dose”: roughly 1 mcg per kilogram of body weight tends to saturate the ghrelin receptor. For an 80 kg (≈176 lb) adult that is about 80 mcg, which is why 100 mcg is such a common starting dose and why the ladder tops out near 200–300 mcg per injection. Pushing a single dose far above the saturation point mostly adds side-effect risk (water retention, tingling) without proportionally more GH release. When more GH exposure is the goal, adding a second or third well-timed dose almost always beats inflating a single one.

How to Reconstitute Ipamorelin

Ipamorelin ships as a lyophilized (freeze-dried) white powder and must be reconstituted with bacteriostatic water before use. In a supervised model, this is prepared by a compounding pharmacy or performed by the patient exactly as the clinic instructs. The math below is provided so you can understand and verify what your provider prescribes — not as a license to source and mix peptides on your own.

Step-by-Step Reconstitution

1. Bring the vial to room temperature and wipe both the peptide vial stopper and the bacteriostatic water vial stopper with a fresh alcohol swab.
2. Draw your chosen volume of bacteriostatic water (BAC water, 0.9% benzyl alcohol preserved) into a reconstitution syringe. The volume you choose sets your final concentration — see the tables below.
3. Inject the water slowly down the inside wall of the vial, aiming the stream at the glass, not directly onto the powder. Never spray it forcefully onto the peptide.
4. Do not shake. Gently swirl or roll the vial between your palms until the powder fully dissolves into a clear, colorless solution. Peptides are fragile; agitation degrades them.
5. Inspect the solution. It should be clear. Discard it if it is cloudy, discolored, or contains particulates.
6. Label and refrigerate. Store reconstituted peptide at 36–46 °F (2–8 °C), protected from light. Use within the window your pharmacy specifies (commonly ~28–30 days).

Understanding Insulin-Unit Math

All dosing is measured on a standard U-100 insulin syringe, where “100 units” = 1 mL and therefore 1 unit = 0.01 mL. Once you know the concentration in micrograms per unit, every dose becomes simple arithmetic:

concentration (mcg per unit) = total mcg in vial ÷ (mL of BAC water × 100)

syringe units to draw = desired dose (mcg) ÷ concentration (mcg per unit)

Dosing Calculation Examples — 5 mg Vial

The 5 mg (5,000 mcg) vial is the most common ipamorelin format. Reconstituting with 2 mL of BAC water gives a clean, forgiving concentration that is easy to measure at typical doses:

• 5,000 mcg ÷ (2 mL × 100) = 25 mcg per unit

If a provider prefers a lower fill volume, the same 5 mg vial reconstituted with 1 mL yields 50 mcg per unit, so 100 mcg = 2 units. That concentration is more potent per unit and harder to measure precisely at small doses, which is why 2 mL is the more common, more forgiving choice.

Dosing Calculation Examples — 10 mg and 2 mg Vials

Ipamorelin is also sold in 10 mg and 2 mg vials. The same formula applies — only the numbers change. The master table below covers every common combination so you can find your exact vial-and-water pairing at a glance. This is gap-fix table (a): vial size × BAC water × concentration × syringe units per dose.

The pattern to internalize: 25 mcg per unit (from 5 mg + 2 mL, or 10 mg + 4 mL) is the most measurement-friendly concentration for standard 100–300 mcg dosing, because it lands your doses on clean, easy-to-read tick marks. Whenever you switch vial sizes, recalculate — never carry a unit count over from a different concentration.

Bacteriostatic vs Sterile Water — Which to Use

Use bacteriostatic water (sterile water containing 0.9% benzyl alcohol) rather than plain sterile water or saline for any peptide you will draw from over multiple days. The benzyl alcohol suppresses microbial growth, which is what allows a reconstituted vial to be used across the ~28–30-day window. Plain sterile water lacks a preservative and is only appropriate for a single-use, same-day preparation. Your compounding pharmacy specifies which to use.

Storage, Handling, and Shelf Life

Lyophilized (unreconstituted) ipamorelin is stable and can be kept refrigerated, or frozen for long-term storage, until you are ready to mix it. Once reconstituted, it must be refrigerated at 36–46 °F (2–8 °C), kept out of light, and never frozen — freezing and thawing degrade the peptide. Do not leave the vial at room temperature longer than necessary during dosing, and always inspect for cloudiness or particulates before each use. Discard at the end of the pharmacy-specified window even if solution remains.

Ipamorelin Administration Guide

Ipamorelin is given by subcutaneous injection — into the fat layer just beneath the skin, not into muscle or vein. The technique is essentially identical to how patients self-administer insulin or GLP-1 medications.

Injection Site Selection

The preferred site is the subcutaneous fat of the abdomen, roughly two inches away from the navel in any direction, avoiding the navel itself. Alternative sites include the outer thigh, the love-handle/flank area, and the back of the upper arm. Key habits:

• Rotate sites with each injection to prevent lipohypertrophy (fatty lumps) and irritation. Many patients keep a simple left/right, upper/lower rotation.
• Avoid areas with visible veins, scars, stretch marks, bruising, moles, or broken skin.
• For fasted morning dosing, the abdomen is convenient; for bedtime dosing, use whichever site is comfortable lying down.

Subcutaneous Injection Technique

1. Wash your hands and clean the chosen site with an alcohol swab; let it air-dry.
2. Draw the prescribed number of units and tap out any air bubbles, expelling them back into the vial.
3. Pinch a fold of skin gently between thumb and forefinger to lift the fat away from muscle.
4. Insert the short insulin needle at a 45–90° angle (90° for most abdomens, 45° for leaner sites) in one smooth motion.
5. Depress the plunger slowly and steadily to deliver the dose, then wait a beat before withdrawing.
6. Withdraw the needle at the same angle, release the pinch, and apply light pressure with a clean cotton pad. Do not rub.
7. Dispose of the needle in a sharps container. Never reuse or recap needles.

Minor redness, itching, or a small welt at the injection site is common and usually transient. Injecting slowly reduces the mild sting some patients notice from the benzyl-alcohol-preserved solution.

Optimal Timing for Ipamorelin Administration

Timing is not a minor detail with ipamorelin — it is central to whether the therapy works as intended, because two things blunt GH release: recent food (especially carbohydrates, which raise insulin and somatostatin) and the body’s own daytime GH suppression.

Why Bedtime

The body’s largest natural GH pulse occurs during early slow-wave sleep. A dose taken 30–60 minutes before bed on an empty stomach amplifies a pulse that is already scheduled to happen, which is why bedtime is considered the flagship dose. If a patient runs only one ipamorelin dose per day, it is almost always the bedtime dose.

Why Fasted

Insulin and elevated blood glucose stimulate somatostatin, the brake on GH release, so injecting in a fed state blunts the response. The practical rule is to inject at least 2–3 hours after your last meal and to wait ~20–30 minutes before eating again, so the GH pulse can occur while insulin is low. Patients who “don’t feel anything” from ipamorelin are frequently dosing too close to food.

Multiple Daily Doses

For intermediate and advanced protocols, additional doses are commonly placed first thing in the morning fasted (before breakfast) and sometimes post-workout, in addition to the bedtime dose. Because each dose produces one discrete pulse, spacing them across the day is how clinicians increase total GH exposure — again, more effectively than inflating any single injection.

Ipamorelin Cycle Length and Protocol Duration

Peptide GH secretagogues are cycled rather than run continuously, both to give the pituitary axis a rest and to reassess whether the therapy is meeting its goals.

• Typical cycle: 8–12 weeks of daily dosing, followed by a break of roughly 4 or more weeks before considering another cycle.
• Extended protocols (12–16 weeks) are used by some experienced patients under close supervision, usually with interim lab checks.
• Why cycle: the theoretical concerns are receptor desensitization and, with sustained supraphysiologic GH/IGF-1, downstream effects on insulin sensitivity. Cycling and lab monitoring mitigate both.
• 5-days-on / 2-days-off weekly patterns are also used within a cycle as a lighter-touch way to preserve receptor sensitivity.

Your clinician sets cycle length against your goals, your IGF-1 trend, and how you tolerate the therapy — there is no one-size-fits-all duration.

Ipamorelin Safety Profile and Potential Side Effects

Ipamorelin’s selectivity is the main reason it is favored over older GH-releasing peptides: it tends not to raise cortisol or prolactin, so the side-effect burden is generally milder than GHRP-6 or GHRP-2. Still, no GH-stimulating therapy is side-effect-free, and long-term safety data specific to wellness use do not exist.

Common Side Effects

• Injection-site reactions — redness, itching, mild swelling, or a transient welt.
• Head-rush, lightheadedness, or headache shortly after dosing.
• Water retention, tingling, or numbness in the hands (paresthesia) — a classic GH-related effect that usually signals the dose is on the higher side.
• Mild increase in appetite — via the ghrelin-receptor action, though far less pronounced than with non-selective secretagogues.
• Facial flushing or a warm sensation in some patients.
• Transient fatigue or vivid dreams, particularly with bedtime dosing.

Contraindications and Cautions

Because ipamorelin raises GH and IGF-1, it is generally avoided or used only with heightened caution in people with:

• Active or prior cancer — IGF-1 is a growth factor, and stimulating it in the presence of malignancy is a theoretical risk; an active-cancer history is typically a firm contraindication.
• Diabetes or significant insulin resistance — sustained GH elevation can reduce insulin sensitivity and raise blood glucose.
• Pregnancy or breastfeeding — never used; no safety data.
• Proliferative retinopathy, uncontrolled thyroid disease, or acromegaly.
• Children/adolescents outside a formal pediatric endocrinology setting.

Athletes must also be aware that growth hormone secretagogues and their releasing peptides are prohibited at all times under the World Anti-Doping Agency (WADA) code (class S2, peptide hormones, growth factors, related substances and mimetics). Ipamorelin falls squarely under this ban; using it will cause a failed drug test in tested sport.

Drug Interactions

• Insulin and other GH secretagogues — combining GH-raising agents can compound effects on glucose and IGF-1; requires careful monitoring.
• Corticosteroids — may blunt the GH response.
• Thyroid medication and antidiabetic drugs — doses may need review as body composition and glucose handling shift.
• Somatostatin analogs — directly oppose the mechanism and would negate the therapy.

Always give your prescriber a full medication and supplement list before starting, and report new symptoms — especially persistent numbness/tingling, vision changes, or rising blood sugar — promptly.

Combining Ipamorelin With Other Peptides and Therapies

Ipamorelin is often used on its own, but it is most famous as half of a stack. The comparison matrix below places it alongside other peptides BHRC clinicians work with, so you can see where each fits by mechanism and goal. Combinations are always physician-directed; peptides are not interchangeable and should never be self-stacked.

Ipamorelin + CJC-1295 (the Classic Stack)

The most common pairing is ipamorelin with CJC-1295 (no-DAC / Mod GRF 1-29). The logic is mechanistic synergy: CJC-1295 (a GHRH analog) increases the amount of GH available for each pulse, while ipamorelin triggers the release and suppresses somatostatin — so the combined pulse is larger than either peptide produces alone, while still preserving the body’s natural pulsatile rhythm. When the two are stacked, ipamorelin is typically dosed at the same 100–300 mcg range described here, matched microgram-for-microgram with CJC-1295. For the full combined protocol, reconstitution math for dual and single vials, and DAC-vs-no-DAC guidance, see our dedicated CJC-1295 & Ipamorelin dosage guide and the CJC-1295 / Ipamorelin treatment page.

Peptide Comparison Matrix

This is gap-fix table (c): a comparison matrix rather than prose, showing how ipamorelin compares to common alternatives by class, target, side-effect profile, and best-studied use.

A frequent question is whether ipamorelin can be run alongside a GLP-1 weight-loss medication. This can be appropriate for some patients — the GH pathway helps preserve lean mass while the GLP-1 drives fat loss — but glucose must be watched closely because the two push insulin sensitivity in opposite directions. That is exactly the kind of decision that belongs with a physician, not a forum.

Ipamorelin vs CJC-1295 vs Sermorelin

These three peptides are constantly compared, and the confusion is understandable because all three ultimately raise growth hormone. The key distinction is which lever they pull. Ipamorelin is a ghrelin-receptor agonist that triggers GH release and removes the somatostatin brake. CJC-1295 and sermorelin are both GHRH analogs that increase the GH the pituitary makes available to release. Because ipamorelin and a GHRH analog act on different receptors, they are complementary partners, not competitors.

In practice, ipamorelin is rarely positioned against CJC-1295 or sermorelin — it is positioned with one of them. Sermorelin is the older, shorter-acting GHRH analog that once held FDA approval (as Geref) before being discontinued for commercial reasons; CJC-1295 no-DAC is its more stable modern counterpart. Whichever GHRH partner a clinician selects, ipamorelin’s job is the same: provide the clean, selective release trigger.

Common Ipamorelin Dosing Mistakes to Avoid

Most problems patients run into are not about the peptide itself but about how it is dosed and handled. These are the errors clinicians see most often — every one of them is a reason supervision matters.

Dosing in a Fed State

Injecting right after a carbohydrate-containing meal blunts the GH response because insulin and glucose stimulate somatostatin. Patients who “don’t feel anything” are frequently dosing in a fed state. The fasted-state rule (2–3 hours after eating, 20–30 minutes before the next meal) is not optional fine print — it is central to whether the therapy works.

Chasing Higher Doses

Because ipamorelin saturates the ghrelin receptor at roughly 1 mcg/kg, pushing a single dose far above ~300 mcg tends to add side effects (water retention, numbness) without proportionally more GH release. More is not better past the saturation point; frequency and timing matter more than a big single dose.

Skipping Labs and Running It Continuously

Titrating without a baseline and follow-up IGF-1, or running ipamorelin indefinitely with no break, forfeits the safety scaffolding of the therapy. Without labs you cannot know whether you are optimized or supraphysiologic, and continuous use risks receptor desensitization and glucose effects.

Mishandling the Reconstituted Vial

Shaking the vial during reconstitution, using plain (non-bacteriostatic) water for a multi-day vial, freezing the reconstituted solution, or leaving it at room temperature all degrade the peptide — sometimes invisibly. A patient who mishandles the vial may conclude “ipamorelin doesn’t work” when the real problem is a denatured product.

Ipamorelin Before and After: Realistic Results Timeline

Patients frequently search for “ipamorelin before and after,” expecting a dramatic transformation photo. Honest expectation-setting matters here: this is a gradual therapy, GH and IGF-1 elevation take time to translate into visible change, and results vary widely with diet, sleep, training, age, and baseline GH status. There are no guaranteed outcomes. The rough timeline patients and clinicians commonly describe:

If a source shows a dramatic four-week “before and after,” treat it skeptically — that pace is not consistent with the underlying physiology of GH optimization, and diet, lighting, and training usually explain most of what a photo shows.

Who Should Consider Ipamorelin Therapy?

In a physician-supervised model, ipamorelin is considered primarily for adults with signs or labs consistent with age-related decline in GH output who have goals around body composition, recovery, and sleep, and who do not have a contraindication. Reasonable candidates often share these features:

• Adults (commonly 30+) noticing slower recovery, changes in body composition, or declining sleep quality.
• Low-normal or declining IGF-1 on labs, without frank GH deficiency requiring recombinant human growth hormone.
• Active people seeking recovery and composition support alongside good training and nutrition (not as a substitute for them).
• No history of cancer, uncontrolled diabetes, pregnancy, or the other contraindications above.
• Willingness to inject on a schedule and to be monitored with periodic labs.

It is not appropriate for tested athletes (WADA-banned), for anyone with active malignancy, during pregnancy, or as a shortcut around foundational lifestyle work. A consultation exists precisely to sort candidacy honestly. Schedule a Peptide Therapy Consultation to get a personalized assessment.

Monitoring Progress and Adjusting Protocols

Supervised peptide therapy is a measure-and-adjust process, not a fixed prescription. Typical monitoring includes:

• Baseline labs before starting: IGF-1, fasting glucose and HbA1c or fasting insulin, and a general metabolic panel. IGF-1 is the practical proxy for GH activity because GH itself is too pulsatile to measure reliably in a single draw.
• Follow-up IGF-1 at roughly 6–8 weeks to confirm the response is in a sensible physiologic range — the goal is optimization, not a supraphysiologic spike.
• Glucose surveillance throughout, since sustained GH elevation can nudge insulin resistance upward.
• Symptom tracking: sleep quality, recovery, water retention, and any paresthesia (numbness/tingling), which typically signals a dose reduction is warranted.
• Dose titration: providers move up the tier ladder only after tolerance is confirmed, and they step down or pause if IGF-1 runs high or side effects appear.

This is why self-administration without labs is discouraged: without an IGF-1 trend and glucose data, you are titrating blind.

Is Ipamorelin FDA-Approved? Legal & Regulatory Status (2026)

Ipamorelin is not FDA-approved for anti-aging, growth-hormone stimulation, body composition, or any other indication. There is no approved drug product, no approved label, and no approved dose. Although ipamorelin advanced through clinical trials for postoperative ileus, it did not receive marketing approval, and any current clinical use occurs outside of FDA approval.

Regulatory status as of July 24, 2026: The compounding pathway for ipamorelin has been in active flux. In September 2023, the FDA placed several peptide bulk drug substances — including ipamorelin — into Category 2 of the interim Section 503A bulk drug substances list, the category for substances the agency believes raise significant safety questions and therefore should not be compounded while under review. Following pushback and the nominators’ withdrawal, the FDA removed ipamorelin acetate from Category 2 on approximately September 20, 2024, and instead routed it through the Pharmacy Compounding Advisory Committee (PCAC) for formal public review; ipamorelin (acetate and free base) was among the substances reviewed at the October 29, 2024 PCAC meeting. Removal from Category 2 does not mean approval to compound — it means the substance was moved out of the “significant safety risk” bucket and remains awaiting a formal committee determination. That review process has continued into 2026. In short, ipamorelin’s eligibility for legal pharmacy compounding remains under ongoing FDA review and subject to change — patients should confirm current status with their prescriber and compounding pharmacy.

Separately, ipamorelin is prohibited in competitive sport at all times under the WADA/USADA code (S2, peptide hormones, growth factors, related substances and mimetics). BHRC does not sell raw or “research-use-only” peptides and does not position ipamorelin as a consumer product; any use is physician-supervised, provider-directed care within the applicable compounding framework.

Conclusion

Ipamorelin is a selective ghrelin-receptor agonist that triggers a clean, pulsatile release of the body’s own growth hormone — comparable in potency to older secretagogues like GHRP-6, but without the cortisol, prolactin, and heavy appetite effects that make those peptides harder to tolerate. In supervised protocols, it is most often dosed at 100–300 mcg per injection, one to three times daily, fasted or at bedtime, on 8–12-week cycles. The reconstitution math is straightforward once you fix a concentration (25 mcg per unit from a 5 mg vial in 2 mL is the most measurement-friendly), and its saturation-dose ceiling means frequency and timing matter more than chasing a large single shot.

The honest caveats are just as important as the numbers: ipamorelin is not FDA-approved, its controlled human data come from short pharmacokinetic and gut-motility studies rather than long-term anti-aging trials, much of the body-composition rationale is mechanistic or from animal models, the regulatory status is actively evolving, and it is banned in tested sport. That is exactly why this belongs under a physician’s care with lab monitoring — not on a self-mixed protocol from a forum. Schedule a Peptide Therapy Consultation with a BHRC physician to find out whether ipamorelin therapy fits your goals, labs, and history.

Frequently Asked Questions About Ipamorelin Dosing

What is the standard ipamorelin dosage?

The most common starting protocol is 100 mcg injected subcutaneously once daily at bedtime on an empty stomach, five days per week. Clinicians titrate upward based on tolerance and IGF-1 labs, most often to 200–300 mcg per dose and sometimes to two or three daily injections (for example, morning fasted, post-workout, and bedtime). Because ipamorelin saturates its receptor near 1 mcg per kilogram of body weight, single doses above ~300 mcg rarely add meaningful growth-hormone release. All figures are provider-directed, not a prescription.

How many units on an insulin syringe is an ipamorelin dose?

It depends entirely on your vial’s concentration. From a 5 mg vial reconstituted with 2 mL of bacteriostatic water (25 mcg per unit), 100 mcg equals 4 units, 200 mcg equals 8 units, and 300 mcg equals 12 units on a U-100 syringe. From a 2 mg vial in 1 mL (20 mcg per unit), 100 mcg equals 5 units. Always recalculate for your specific fill volume rather than copying someone else’s unit count.

How do I reconstitute a 5 mg ipamorelin vial?

Wipe both stoppers with alcohol, draw your prescribed volume of bacteriostatic water, and inject it slowly down the inside wall of the vial rather than onto the powder. Swirl gently — never shake — until the solution is clear, then refrigerate. Adding 2 mL of bacteriostatic water to a 5 mg vial gives 2,500 mcg per mL, or 25 mcg per insulin unit, so a 100 mcg dose equals 4 units. Reconstitution should be done exactly as your compounding pharmacy or clinic directs.

When is the best time to inject ipamorelin?

Bedtime on an empty stomach is the flagship dose, because it amplifies the large growth-hormone pulse that naturally occurs in early deep sleep. Inject at least 2–3 hours after eating (especially carbohydrates) and wait about 20–30 minutes before your next meal, since insulin and glucose suppress GH release. If additional daily doses are used, they are commonly placed first thing in the morning fasted and sometimes post-workout.

How long should an ipamorelin cycle be?

A typical cycle is 8–12 weeks of daily dosing followed by a break of about four or more weeks before considering another cycle. Some experienced patients run 12–16 weeks under close supervision with interim labs. Cycling helps preserve receptor sensitivity and gives an opportunity to reassess IGF-1 and results before continuing.

What are the side effects of ipamorelin?

The most common are injection-site reactions, a head-rush or lightheadedness after dosing, headache, water retention, and tingling or numbness in the hands, which can signal the dose is too high. A mild increase in appetite can occur via the ghrelin-receptor action, but it is far less pronounced than with non-selective secretagogues because ipamorelin is selective and does not meaningfully raise cortisol or prolactin. Report persistent numbness, vision changes, or rising blood sugar to your provider.

Is ipamorelin better than CJC-1295 or sermorelin?

They are not really rivals — they act on different receptors. Ipamorelin is a ghrelin-receptor agonist that triggers the growth-hormone pulse, while CJC-1295 and sermorelin are GHRH analogs that increase the amount of GH available to release. That is why ipamorelin is usually combined with one of them rather than compared against it. Ipamorelin’s advantage within its own class (versus GHRP-6 or GHRP-2) is selectivity: a strong GH pulse without a cortisol or prolactin spike.

Does ipamorelin build muscle or burn fat?

Research suggests growth-hormone and IGF-1 optimization can support lean-mass retention and reduce visceral fat, and patients commonly report better recovery and body composition over 8–12 weeks. However, the effects are gradual and modest, depend heavily on training, nutrition, and sleep, and ipamorelin has not been tested in a long-term human trial for muscle gain or fat loss. It is a supportive therapy, not a replacement for diet and exercise, and results are not guaranteed.

Is ipamorelin legal and FDA-approved?

Ipamorelin is not FDA-approved for any use. As of July 24, 2026, its eligibility for legal pharmacy compounding is under ongoing FDA review — it was placed in 503A Category 2 in September 2023, then removed from Category 2 around September 2024 and routed to the Pharmacy Compounding Advisory Committee for formal review, a process still unresolved. Removal from Category 2 is not the same as approval to compound. Ipamorelin is also banned at all times in tested sport under the WADA code.

Can I take ipamorelin with a GLP-1 medication like semaglutide or tirzepatide?

Some physicians do combine a growth-hormone secretagogue with a GLP-1 medication so ipamorelin helps preserve lean mass while the GLP-1 drives fat loss. But the two push insulin sensitivity in opposite directions, so blood glucose must be monitored closely, and the decision should be made and supervised by a physician — never self-stacked. Discuss it during a consultation before combining any peptides or medications.

References

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822. pubmed.ncbi.nlm.nih.gov/9849822
2. Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. DOI: 10.1023/A:1018955126402. link.springer.com — Gobburu 1999 (PMID not independently verified — see internal-link TODO.)
3. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. DOI: 10.1007/s00384-014-2030-8. link.springer.com — Beck 2014 (PMID not independently verified — see internal-link TODO.)
4. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207. pubmed.ncbi.nlm.nih.gov/28400207
5. Johansen PB, Nowak J, Skjærbæk C, Flyvbjerg A, Andreassen TT, Wilken M, Ørskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. (PMID not independently verified — see internal-link TODO.)
6. Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. ~2000. (PMID not independently verified — see internal-link TODO.)
7. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov — 503A bulk drug substances
8. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting Materials, October 29, 2024 (503A bulk drug substances nominations, including ipamorelin). fda.gov — Oct 29, 2024 PCAC materials

Related Resources / Related Guides from BHRC

• CJC-1295 & Ipamorelin Dosage Guide — the full combined-stack protocol, dual-vial reconstitution math, and DAC vs no-DAC guidance.
• CJC-1295 / Ipamorelin therapy at BHRC — treatment overview and consultation.
• Tesamorelin — FDA-approved stabilized GHRH analog for visceral fat reduction.
• Sibling dosage guides in this batch — CJC-1295/Ipamorelin, Tirzepatide, Retatrutide, PT-141, MOTS-c, and BPC-157 — are being published alongside this one. Ask a BHRC physician which peptide protocol fits your goals.

Reminder: This guide is educational and not a substitute for individualized medical care. Ipamorelin is not FDA-approved, is not sold by BHRC as a consumer product, and should only be used under physician supervision with appropriate lab monitoring.